|
|
Research progress on biomarkers for predicting immunotherapy efficiency in small cell lung cancer |
You Meiyi, Zhong Ting, Kong Chunchu |
4th Respiratory Department the First Affiliated Hospital of Hunan Normal University Hunan Provincial People's Hospital Changsha
410013 Hunan China |
|
|
Abstract Platinum-based chemotherapy has long been the standard first -line treatment for small cell lung cancer. In recent
years immunotherapy has rapidly advanced in the field of lung cancer offering new hope for small cell lung cancer patients. However
the response rate and duration of response to immunotherapy remain suboptimal primarily due to the limitations of current biomarkers
for predicting immunotherapy efficacy in small cell lung cancer such as low sensitivity and weak specificity. therefore there is an
urgent clinical need to identify more efficient biomarkers. The research on immune checkpoint-related markers such as PD-L1 and
B7-H3 has shown that the expression levels of immune checkpoint proteins are closely related to the response to immunotherapy in
some patients. In terms of tumor-specific biomarkers tumor mutation burden TMB has been widely utilized as a key indicator for
predicting the efficacy of immunotherapy while molecular subtyping of small cell lung cancer offers new perspectives for optimizing
treatment strategies. Furthermore tumor microenvironment - related biomarkers including the inflammatory T cell gene expression
profile T cell inf GEP and tumor - infiltrating lymphocytes TILs provide additional possibilities for evaluating immune
responses. In the field of non-invasive testing peripheral blood biomarkers such as the neutrophil-to-lymphocyte ratio NLR and
lung immune prognostic index LIPI have demonstrated promising predictive value for therapeutic outcomes. This article reviews the
research progress of potential biomarkers in the field of small cell lung cancer in recent years aiming to explore suitable biomarkers for
identifying patients who will derive long-term benefit realizing individualized precision treatment improving patients' quality of life
and prolonging survival time.
|
|
|
|
|
|
|
|